Feasibility of Endovascular Repair of Ascending Aortic Pathologies

NCT ID: NCT03322033

Last Updated: 2022-03-08

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-12-15
• Study Completion Date: 2028-01-15

Brief Summary

The purpose of this early feasibility study is to investigate the outcome of selected patients with ascending thoracic aortic pathologies including type A aortic dissection, who are suitable for endovascular repair with the Medtronic Valiant PS-IDE Stent Graft System with the Captivia Delivery System (or the Valiant PS-IDE Stent Graft).

Detailed Description

The purpose of this early feasibility study is to investigate the outcome of selected patients with ascending aortic pathologies including type A aortic dissection, retrograde type A aortic dissection, who are suitable for endovascular repair with the Valiant PS-IDE Stent Graft device. The investigators propose to study patients with Dissections affecting the aorta between the Sinus of Valsalva and the innominate artery orifice (with no involvement of aortic valve). In these patients, the ascending aorta will be repaired using the stent graft. For patients with type A aortic dissection, the investigators expect to reroute the blood to the true lumen by covering the proximal tear. In patients with retrograde type A aortic dissection, there might or might not be additional tears in the ascending aorta. If they are tears in ascending aorta, these dissections behave similarly like a type A aortic dissection, in which all the tears in the ascending aorta need to be covered. If the proximal tear is only in the descending thoracic aorta, these patients will require coverage in the ascending aorta with the stent graft along with coverage of proximal tear in the descending thoracic aorta using Valiant stent graft.

Patients will be selected from a high-risk surgical cohort. The total number of enrolled subjects is planned to be 20.

Conditions

Dissection of Thoracic Aorta

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Type A Dissection

High risk subjects with ascending thoracic aortic pathologies including type A aortic dissection who are suitable for endovascular repair

Group Type: EXPERIMENTAL

Valiant PS-IDE Stent Graft

Intervention Type: DEVICE

Medtronic Valiant PS-IDE Stent Graft System with the Captivia Delivery System

Interventions

Valiant PS-IDE Stent Graft

Medtronic Valiant PS-IDE Stent Graft System with the Captivia Delivery System

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• In order to qualify for this physician-sponsored Investigational Device Exemption, the patients would have to meet the entire entry criteria listed below, sign a consent approved by the FDA and IRB, and agrees to follow-up according to the study protocol.

• Patient must have a type A thoracic aortic dissection, retrograde type A thoracic aortic dissection of the ascending thoracic aorta affecting the area between the Sinus of Valsalva and the innominate artery orifice (with no involvement of the aortic valve) and be considered a candidate for endovascular repair;

• The proximal and distal landing zones for placement of graft should be at least 1 cm.
• The proximal landing zone will allow placement of the stent graft as to not inhibit valvular function, occlude a coronary ostium or proximal bypass graft; The aortic root may be dissected, but the proximal tear site must be at least 1cm from the STJ (and within the above listed size criteria).
• Distal landing zone must allow for continued perfusion of critical cerebral vessels;
• The aorta as measured adventitial wall to adventitial wall must be greater than 28 mm and no more than 44 mm maximum diameter at both the proximal and distal landing zone.
• The patient must be high-risk surgical candidate according to the following established criteria: ASA score of IV.

Exclusion Criteria

• Pregnant or pediatric patients (younger than 21 years of age);
• Patients who have a condition that threatens to infect the stent graft/aortic valve prosthesis;
• Patients with allergies to the stent graft material;
• Patients or their legally authorized representative (LAR) who do not sign the informed consent;
• Patients with expected survival less than one year due to a condition other than the ascending aortic

• Minimum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medtronic

INDUSTRY

Sponsor Role: collaborator

Baylor Research Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

William Brinkman, MD

Role: PRINCIPAL_INVESTIGATOR

Cardiac Surgery Specialists

Locations

Baylor Scott & White The Heart Hospital

Plano, Texas, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Megan C White, BA

Role: CONTACT

megan.white1@bswhealth.org

469-814-4720

Facility Contacts

Pauline Matheri

Role: primary

pauline.matheri@bswhealth.org

Megan White

Role: backup

megan.white1@bswhealth.org

Other Identifiers

G170196

Identifier Type: -

Identifier Source: org_study_id